Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Ovarian Epithelial 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Follicular 4Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Neoplasms by Histologic Type 1

Interventions

avapritinib 4midostaurin 3masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mastocytosis, Systemic × denileukin diftitox × Clear all
NCT00493129 2012-02-08

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡